BIOCON BIOLOGICS INDIA LIMITED

Biocon Biologics India Limited Company Introduction

Biocon Biologics India Limited is a global biopharmaceutical company and a subsidiary of Biocon Ltd., headquartered in Bengaluru, India. It is a leading player in the development, manufacturing, and commercialization of biosimilars and novel biologics. The company focuses on therapeutic areas such as diabetes, oncology, immunology, and ophthalmology. Biocon Biologics has a strong pipeline of biosimilar products, including insulin glargine, trastuzumab, pegfilgrastim, and bevacizumab, which are approved and marketed in various regulated and emerging markets worldwide. The company is committed to making affordable access to life-saving biologics a reality for patients globally through its vertically integrated capabilities spanning research and development, manufacturing, and global commercialization.

Factory or Trader: Manufacturer (Factory)

Biocon Biologics India Limited is a manufacturer. The company possesses extensive research and development capabilities, state-of-the-art manufacturing facilities, and a robust global supply chain to produce its biopharmaceutical products. They are directly involved in the entire process from drug discovery and development to large-scale production.

Products Manufactured or Sold:

- Insulin Glargine (biosimilar to Lantus)

- Trastuzumab (biosimilar to Herceptin)

- Pegfilgrastim (biosimilar to Neulasta)

- Adalimumab (biosimilar to Humira)

- Bevacizumab (biosimilar to Avastin)

- Insulin Aspart (biosimilar to Novolog/Novorapid)

- Recombinant Human Insulin (rh-insulin)

Key pipeline products in development or regulatory review:

- Ustekinumab (biosimilar to Stelara)

- Denosumab (biosimilar to Prolia/Xgeva)

- Aflibercept (biosimilar to Eylea)